Figure 1.
Analysis of JAK2 VAFs in peripheral blood. (A) Comparison of JAK2 VAF measured in RNA from granulocytes (GRA) vs platelets (PLT). Dashed lines connect data points from the same patient. (B) Comparison of JAK2 VAF measured in RNA from granulocytes vs reticulocytes (RET). (C) JAK2 VAF in purified cell populations from peripheral blood. Boxes represent 50% of the measured values; whiskers indicate the range; and horizontal lines indicate the median. The JAK2 VAF of 22 patients measured in DNA or RNA from different peripheral blood lineages is shown below. Numbers in the cells of the table indicate the percentages of JAK2 VAF; the shading of boxes corresponds to the ranges shown on the right. (D) Patterns of lineage contribution of the JAK2-mutant cells derived from the data presented in panels A and B. **P < .01; ***P < .001; ****P < .0001. B, B cell; MO, monocyte; NK, natural killer cell; ns, not significant; T, T cell; UPN, unique patient number.

Analysis of JAK2 VAFs in peripheral blood. (A) Comparison of JAK2 VAF measured in RNA from granulocytes (GRA) vs platelets (PLT). Dashed lines connect data points from the same patient. (B) Comparison of JAK2 VAF measured in RNA from granulocytes vs reticulocytes (RET). (C) JAK2 VAF in purified cell populations from peripheral blood. Boxes represent 50% of the measured values; whiskers indicate the range; and horizontal lines indicate the median. The JAK2 VAF of 22 patients measured in DNA or RNA from different peripheral blood lineages is shown below. Numbers in the cells of the table indicate the percentages of JAK2 VAF; the shading of boxes corresponds to the ranges shown on the right. (D) Patterns of lineage contribution of the JAK2-mutant cells derived from the data presented in panels A and B. **P < .01; ***P < .001; ****P < .0001. B, B cell; MO, monocyte; NK, natural killer cell; ns, not significant; T, T cell; UPN, unique patient number.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal